Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors
April 8, 2022
April 8, 2022
March 31, 2022
March 24, 2022
March 8, 2022
February 9, 2022
February 8, 2022
January 6, 2022
January 5, 2022
December 13, 2021
December 9, 2021